Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cal Era: HAIC + Lenvatinib + Camrelizumab in Unresectable HCC
NCT05003700Phase 2Completed
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Aug 2021
- Primary completion
- May 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, lenvatinib in hepatocellular carcinoma (HCC), sponsored by Nanfang Hospital, Southern Medical University. Started Aug 2021; status: completed.
02
Drugs
camrelizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05003700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05003700.